Recordati Ireland Limited

Recordati Industria Chimica E Farmaceutica S.p.a.

Smithkline Beecham Corporation

Recordati Industria Chimica E Farmacentica S.p.a.

Davide Graziani

Carlo Riva

Patrizia Angelico

Elena Poggesi

Carlo De Toma

Amedeo Leonardi

Gianni Motta

Sergio Menegon

Matteo Longhi

Silvano Ronzoni

Giulio Dondio

Luciano Guarneri

Katia Dimitrova Karamfilova

Pier Andrea Gatti

Valerio Tazzari

Fabio Frigerio

Elisa Callegari

Elena Poggessi

Matteo Marco Longhi

This invention relates to compounds of formula I; and their use as antagonists of P2Xand P2Xreceptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of pain and chronic pain and tolerance to analgesic, respiratory disorders and dysfunctions, and treatment of overactive bladder, bladder pain syndrome, dysuria and in general in genitourinary diseases, cardiovascular disorders and more in general for the potential treatment of visceral organ diseases and disorders characterized by the involvement of P2Xand P2Xreceptors.

P2Xreceptor antagonists

Disclosed are triazole, imidazole and pyrrole condensed piperazine derivatives and their use as allosteric modulators of mGlus receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related either directly or indirectly to glutamate dysfunction, i.e., disorders treatable by positive allosteric modulation (PAM) or by negative allosteric modulation (NAM) of mGluR. 

Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of mGlu5 receptors

This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction. 

Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors

This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors

The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

Spiroheterocyclic compounds as mGlu5 antagonists

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

Heterocyclic derivatives as M-GLU5 antagonists

Heterocycle-condensed morphinoid derivatives (II)

Growing community of inventors

Milan, Italy

Davide Graziani